In a phase II study, 2 was administered twice a day (3 or 6 mg/kg/d) with a cholinesterase inhibitor and/or memantine (an NMDA antagonist) for 24 weeks to mild-to-moderate AD patients [128]. The gene discussed is BCHE; the disease is Alzheimer disease.